Multiple Sclerosis Prediction and Monitoring of Progression Study

Launched by UNIVERSITY HOSPITAL, GHENT · Jan 5, 2023

Keywords

ClinConnect Summary

The Multiple Sclerosis Prediction and Monitoring of Progression Study is focused on understanding and tracking the progression of multiple sclerosis (MS), particularly the progressive forms of the disease. MS is a condition where the immune system attacks the central nervous system, leading to various symptoms and, in some cases, a gradual decline in function over time. This study aims to find new ways to detect early signs of progression by using technology that monitors patients in their everyday lives, rather than just during clinical visits. Researchers will compare these new digital tools to standard testing methods to see how well they work.

To participate in the study, individuals aged 18 to 60 with certain types of MS or healthy controls who need a specific sleep test may be eligible. However, those with certain health issues or recent changes in their condition may not qualify. Participants can expect to wear devices that track their health and take part in assessments that help researchers gather important information about the progression of MS. This study hopes to improve how we understand and treat MS, making it easier for patients to get the care they need.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Relapsing Remitting (RR) or Primary Progressive (PPMS) MS as defined by 2017 Mc Donald criteria, or Secondary Progressive (SPMS) according to Lorscheider criteria AND having an EDSS ≤ 6.5
• • Healthy control
• • Non-MS Patient with an indication for polysomnography
• • Age 18-60 years inclusive
• Exclusion Criteria:
• • Patients who were prescribed 4-aminopyridin during the last 30 days.
• • Patients with severe cardiac, pneumological, neurological, hematological, immunological, infectious, rheumatoid, endocrinological, gastro-intestinal, urological comorbidity that may interfere with outcome measures as determined by the investigators.
• • Confirmed clinical relapses or new lesions on MRI during the last six months
• • Known allergy to electrodes used as part of the study protocol
• • Having an implanted device, such as (but not limited to) a pacemaker, cardioverter defibrillator (ICD), and/or neural stimulation device.